A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease Followed by an Open-Label Extension Phase
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Dupuytren's contracture
- Focus Registrational; Therapeutic Use
- Acronyms CORD-II
- Sponsors Auxilium Pharmaceuticals; Endo Pharmaceuticals
- 08 May 2014 According to a Biospecifics Technologies Corporation media release, the supplement biologics license application (sBLA) for potential label expansion of Xiaflex is under FDA review with a PDUFA date of October 20, 2014.
- 21 Oct 2013 New trial record